We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+54.95%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$322M
Cap. Flow
+$104M
Cap. Flow %
9.75%
Top 10 Hldgs %
58.42%
Holding
77
New
21
Increased
11
Reduced
14
Closed
24

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$67.6M
2
GPCR icon
Structure Therapeutics
GPCR
+$32.7M
3
AMAM
Ambrx Biopharma Inc
AMAM
+$22.6M
4
VTYX
Ventyx Biosciences
VTYX
+$16.9M
5
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$14.1M

Top Sells

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$23.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$19.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$16.9M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$15.4M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 83.95%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOBT
51
DELISTED
IO Biotech
IOBT
$928K 0.09%
493,827
– –
IMUX icon
52
Immunic
IMUX
$182M
$632K 0.06%
42,118
– –
NUVB.WS
53
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$4K ﹤0.01%
66,666
– –
ALXO icon
54
ALX Oncology
ALXO
$268M
– –
-1,000,000
Closed -$4.8M
BBIO icon
55
CALL
BridgeBio Pharma
BBIO
$16.8B
– –
-500,000
Closed -$13.2M
BBIO icon
56
BridgeBio Pharma
BBIO
$16.8B
– –
-400,000
Closed -$10.5M
CRNX icon
57
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-250,000
Closed -$7.43M
ETNB
58
DELISTED
89bio
ETNB
– –
-310,000
Closed -$4.79M
GERN icon
59
Geron
GERN
$930M
– –
-2,750,000
Closed -$5.83M
IMTX icon
60
Immatics
IMTX
$1.19B
– –
-1,050,000
Closed -$12.2M
KALV
61
DELISTED
KalVista Pharmaceuticals
KALV
– –
-900,000
Closed -$8.67M
CYPH
62
Cypherpunk Technologies Inc
CYPH
$65.4M
– –
-354,266
Closed -$489K
MRUS
63
DELISTED
Merus
MRUS
– –
-245,000
Closed -$5.78M
NBIX icon
64
Neurocrine Biosciences
NBIX
$18.4B
– –
-150,000
Closed -$16.9M
ROIV icon
65
Roivant Sciences
ROIV
$24.3B
– –
-1,200,000
Closed -$14M
RPTX
66
CALL
DELISTED
Repare Therapeutics
RPTX
– –
-500,000
Closed -$6.04M
RYTM icon
67
Rhythm Pharmaceuticals
RYTM
$7.41B
– –
-400,000
Closed -$9.17M
SLNO
68
DELISTED
Soleno Therapeutics
SLNO
– –
-125,000
Closed -$3.69M
SRPT icon
69
Sarepta Therapeutics
SRPT
$1.63B
– –
-200,000
Closed -$19.2M
TYRA icon
70
Tyra Biosciences
TYRA
$1.84B
– –
-31,872
Closed -$439K
VERV
71
DELISTED
Verve Therapeutics
VERV
– –
-215,000
Closed -$2.85M
VIGL
72
DELISTED
Vigil Neuroscience
VIGL
– –
-188,390
Closed -$1.02M
ZURA icon
73
Zura Bio
ZURA
$526M
– –
-424,000
Closed -$2.8M
CERE
74
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-700,000
Closed -$15.3M
LIAN
75
DELISTED
LianBio American Depositary Shares
LIAN
– –
-280,000
Closed -$417K
1 2
3
4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2023 Portfolio in Review

As of Q4 2023, Logos Global Management held 77 positions worth $1.07B, up 43% from $750M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Logos Global Management deployed $104M of net new capital in Q4 2023, opening 21 new positions and adding to 11 existing holdings. Its largest new stake was argenx: 145,000 shares worth $55.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Icosavax, Inc. Common Stock, an estimated $23.7M trimmed.

  • Logos Global Management's largest Q4 2023 buy was argenx: 145,000 shares worth $55.2M.
  • Logos Global Management added most to Structure Therapeutics in Q4 2023, an estimated $32.7M increase.
  • Logos Global Management's biggest Q4 2023 reduction was Icosavax, Inc. Common Stock, cutting an estimated $23.7M.
  • Logos Global Management fully exited Sarepta Therapeutics in Q4 2023, selling an estimated $19.2M.
  • Logos Global Management's ten largest holdings make up 58% of its $1.07B portfolio in Q4 2023.
  • Logos Global Management opened 21 new positions and closed 24 in Q4 2023.
  • Logos Global Management's portfolio value rose 43% quarter-over-quarter to $1.07B.

Based on Logos Global Management's 13F filing for Q4 2023, filed 14 Feb 2024.